Kyverna Therapeutics, Inc.
Data quality: 83%
KYTX
Nasdaq
Manufacturing
Chemicals
$9.38
▲
$0.16
(1.74%)
Mkt Cap: 567.07 M
Price
$9.38
Mkt Cap
567.07 M
Day Range
$9.10 — $9.55
52-Week Range
$1.78 — $13.67
Volume
444,287
Open $9.15
50D / 200D Avg
$8.25
13.72% above
50D / 200D Avg
$6.46
45.30% above
Quick Summary
Key Takeaways
Negative free cash flow of -153.72 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-95.92%
Below sector avg (-53.41%)
ROIC-78.92%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio5.16
Interest Coverage-347.29
Valuation
PE (TTM)
-3.52
Below sector avg (-1.48)
P/B Ratio3.73
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -3.5 | -1.5 |
| P/B | 3.7 | 1.6 |
| ROE % | -95.9 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
ETFs Holding This Stock
0.00% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -161.31 M |
| ROE | -95.92% | ROA | -77.99% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -153.72 M |
| ROIC | -78.92% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5.16 |
| Interest Coverage | -347.29 | Asset Turnover | N/A |
| Working Capital | 141.05 M | Tangible Book Value | 151.95 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3.52 | Forward P/E | N/A |
| P/B Ratio | 3.73 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -27.11% | ||
| Market Cap | 567.07 M | Enterprise Value | 532.91 M |
| Per Share | |||
| EPS (Diluted TTM) | -3.64 | Revenue / Share | N/A |
| FCF / Share | -2.54 | OCF / Share | -2.54 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 95.29% |
| SBC-Adj. FCF | -163.37 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | — | — |
| Net Income | -161.31 M | -127.48 M |
| EPS (Diluted) | -3.64 | -3.33 |
| Gross Profit | — | — |
| Operating Income | -169.83 M | -142.60 M |
| EBITDA | — | — |
| R&D Expenses | 133.72 M | 112.47 M |
| SG&A Expenses | — | — |
| D&A | 1.80 M | 2.13 M |
| Interest Expense | 489,000.0 | 142,000.0 |
| Income Tax | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 293.83 M | 304.65 M |
| Total Liabilities | 61.55 M | 38.06 M |
| Shareholders' Equity | 232.28 M | 266.59 M |
| Total Debt | — | — |
| Cash & Equivalents | 124.09 M | 96.62 M |
| Current Assets | 282.95 M | 290.60 M |
| Current Liabilities | 36.49 M | 33.76 M |
{"event":"ticker_viewed","properties":{"ticker":"KYTX","listing_kind":"stock","pathname":"/stocks/kytx","exchange":"Nasdaq","country":"US"}}
